One of the most common questions myeloma patients ask me is: Should I get a stem cell transplant, and if so when should I do it?

The update of the IFM trial at #ASH20 addresses this question. ash.confex.com/ash/2020/webprโ€ฆ #ASH20VR

Thread ๐Ÿ‘‡
1) Should eligible patients do a transplant: Yes

Two RCTs show an Overall Survival benefit of transplant over chemo alone.

2) Does timing early vs delayed matter?

4 RCTs (including IFM 2009) show similar overall survival regardless of when transplant is done (early vs delayed)
The IFM 2009 results show identical overall survival ~60% at 8 years with early or delayed transplant, even though not everyone who is in the delayed transplant group even gets to a transplant. But there are important caveats.
1) All patients in IFM trial were <65. This strategy wonโ€™t work for many older patients whom we consider for transplant.

2) We have other data that for high risk patients survival is better with early transplant

3) There are insurance and storage issues with delayed transplant
4) In many countries transplant is less expensive than drugs used instead of transplant.

5) Longer PFS with early transplant means get time without any big chemo treatments

6) Early transplant allows us to double dip: In selected patients we can consider second transplant.
So my default preference is early transplant followed by maintenance for most patients with myeloma. But if standard risk patients, age<65 are keen on delaying transplant, I would heed the patients wishes & counsel them that their choice is unlikely to compromise overall survival
In summary, auto transplant is like a very effective drug for myeloma & improves survival. We prefer early transplant for various reasons. But IFM data show that in the VRd era delayed transplant produces identical 8yr survival rates. Patient preference must be taken into account

โ€ข โ€ข โ€ข

Missing some Tweet in this thread? You can try to force a refresh
ใ€€

Keep Current with Vincent Rajkumar

Vincent Rajkumar Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @VincentRK

3 Dec
Follow and search #ASH20VR for my commentaries (&critiques) on important myeloma related abstracts during #ASH20.

I have used these personal hashtags selectively to avoid information overload. Check #ASH19VR for last years picks. @MyelomaTeacher @NorthTxMSG @grpetersen1
I started doing personal hashtags at meetings a few years ago for my own selfish reasons. It has worked out great for me. And Iโ€™m hoping itโ€™s useful for others.
I tweet a lot at ASH and other Hematology/oncology meetings but wonโ€™t add my personal hashtag unless I feel like itโ€™s something very important that I would want to look up in the future.
Read 4 tweets
1 Dec
Should we screen for myeloma in high risk individuals?

For Blacks with one or more affected first-degree relatives, & all others with 2 or more affected first-degree relatives โ€” Yes.

Iโ€™ve come to this conclusion after considering pros & cons. @nature nature.com/articles/d4158โ€ฆ
If you are going to offer screening, I suggest only a one-time year at age 50 and older, or 10 years before diagnosis in first degree relative.

Test: SPEP, Serum IFE, and Serum FLC. We are not screening for MGUS, but for evidence suggestive of high risk SMM or MM.
This recommendation affects a small number of people who are at high risk of developing SMM or MM. For all others, including general population, wait till results of iSTOP MM RCT, and other studies such as PROMISE. @sykristinsson @IreneGhobrial
Read 4 tweets
23 Nov
3 for 3!

@AstraZeneca @UniofOxford vaccine highly effective against COVID. Lower cost, easier storage & transport. This is also the vaccine that @SerumInstIndia is manufacturing: means great news for India. @nramind @rameshlaus @sumanthraman @DrEricDing nytimes.com/live/2020/11/2โ€ฆ
This comes on the heels of great results from @pfizer and @moderna_tx

With the pandemic affecting the whole world, we need all the vaccines we can get. Iโ€™m very pleased with the efficacy. I wouldnโ€™t worry about 70% versus 95%. Efficacy is efficacy. @singersrinivas @ShirleySetia
The @UniofOxford @AstraZeneca vaccine is an adenovirus vector vaccine. See mechanism of action and doses reserved by country. @business @PSampathkumarMD ๐Ÿ‘‡
Read 7 tweets
13 Nov
Here are my Top 5 #ASH20 @ASH_hematology myeloma abstracts. #ASH20VR
Iโ€™ve listed them with links to the full abstract. @mtmdphd @Rfonsi1 @MayoMyeloma @NorthTxMSG @Mohty_EBMT @BldCancerDoc @szusmani @ninashah33 @profghjackson @Phari @PerrotAurore @mvmateos
Thread for countdown๐Ÿ‘‡
#5 Allogeneic off-the-shelf CAR-T therapy for myeloma. First in human results with Anti BCMA ALLO-647 shows clinical activity in myeloma.
5 of 15 responses. #ASH20 #ASH20VR @sloan_kettering @Phari @AllogeneTx ash.confex.com/ash/2020/webprโ€ฆ
#4 Identification of a potential mechanism for frequent relapses after CAR-T therapy for myeloma: Bi allelic loss of BCMA locus at 16p. Important work. #ASH20 #ASH20VR @DanaFarber @NoopurRajeMD

ash.confex.com/ash/2020/webprโ€ฆ
Read 8 tweets
13 Nov
Whether it is masks or meds consider ๐™ฌ๐™๐™–๐™ฉ ๐™ž๐™› ๐™ฌ๐™š ๐™–๐™ง๐™š ๐™ง๐™ž๐™œ๐™๐™ฉ, as well as๐™ฌ๐™๐™–๐™ฉ ๐™ž๐™› ๐™ฌ๐™š ๐™–๐™ง๐™š ๐™ฌ๐™ง๐™ค๐™ฃ๐™œ

For benign interventions (eg., masks for COVID) if we say masks work & they donโ€™t, consequence is small. If we say they donโ€™t when they truly do, itโ€™s tragic
For any intervention we have to always consider the consequences of a Type I error relative to the consequences of a Type 2 error.

For many medicines, the consequences of a Type 1 error in terms of toxicity, harm, & cost usually outweighs those of a Type II error. We need RCTs.
Sometimes there are interventions where consequences of erroneously concluding something is effective when it is not (Type I error) is small compared to concluding itโ€™s not effective when it actually is (Type II error). Eg., hand washing to prevent COVID. Masks are like that.
Read 4 tweets
11 Nov
COVID thoughts

Iโ€™m happy that we rapidly found stuff that works:
-Masks
-Proning
-Dexamethasone
-Monoclonal antibodies
-Upcoming vaccine

Iโ€™m disappointed about the many mistakes:
-Lack of a comprehensive strategy
-Mixed messages
-Politicization of masks
-PPE shortage
As a result of our success we have lowered the number of deaths. But the daily death toll is unacceptably high: ~1000 per day. How can we possibly lower it when the number of new cases is skyrocketing? ImageImage
If you compare to Europe, you could come to the conclusion that nothing matters. Itโ€™s just the way COVID is. But we have to ask, have they made the same mistakes as us? ImageImage
Read 7 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!